Arif Habib, MD
Psychiatry · Granite City, ILNPI 1215912977
Payments from drug & device makers
Across 82 payments — averaging $145.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$6K
- Sunovion Pharmaceuticals Inc.$4K
- Johnson & Johnson$282
- AbbVie$184
- Otsuka America Pharmaceutical, Inc.$100
- Alkermes, Inc.$93
- plus $520 from 11 others
What the payments were for
- Speaking & faculty fees$4,10574%
- Travel & lodging$1382%
- Food & beverage$1,24923%
- Education$461%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 5 | $6,361 |
| Sunovion Pharmaceuticals Inc. | 4 | $4,359 |
| Johnson & Johnson | 16 | $282 |
| AbbVie(2 entities) | 14 | $184 |
| Otsuka America Pharmaceutical, Inc. | 6 | $100 |
| Alkermes, Inc. | 6 | $93 |
| Neurocrine Biosciences, Inc. | 5 | $87 |
| Avanir Pharmaceuticals, Inc. | 5 | $72 |
| Teva Pharmaceuticals USA, Inc. | 5 | $62 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $55 |
| Vanda Pharmaceuticals Inc. | 2 | $50 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Lundbeck LLC | 1 | $39 |
| Orexo US, Inc. | 1 | $27 |
| Acadia Pharmaceuticals Inc | 1 | $22 |
| Indivior Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LATUDA$4,359
How this compares
$11,899 in reported general payments places this provider in the 90th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 126 | $408,472 |
| IngrezzaValbenazine Tosylate | 12 | $186,502 |
| AustedoDeutetrabenazine | 19 | $144,169 |
| Invega TrinzaPaliperidone Palmitate | 14 | $99,739 |
| Risperdal ConstaRisperidone Microspheres | 67 | $64,699 |
| VraylarCariprazine Hcl | 47 | $64,320 |
| RexultiBrexpiprazole | 41 | $55,648 |
| Abilify MaintenaAripiprazole | 19 | $46,253 |
| Chlorpromazine Hcl | 58 | $23,303 |
| VivitrolNaltrexone Microspheres | 11 | $17,977 |
| Lurasidone Hcl | 99 | $16,039 |
| Paliperidone ErPaliperidone | 69 | $15,847 |
| Buspirone Hcl | 882 | $14,707 |
| Clozapine | 118 | $12,861 |
| Quetiapine Fumarate | 737 | $12,781 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $282 | $572,909207 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $87 | $186,50212 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $62 | $144,16919 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $100 | $101,90160 claims |
| AbbVieVraylar | $184 | $64,32047 claims |
| Alkermes, Inc.Vivitrol | $93 | $17,97711 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $44 | $8,98620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Granite City
- Jeffrey RossNorthbrook$10.8M
- Yuhwen ChowChicago$8.5M
- Mark LermanNorthbrook$4.5M
- Danesh AlamWinfield$2.7M
- John ZajeckaSkokie$2.5M
- Riaz BaberNaperville$2.4M
- Michael GreenbaumLibertyville$2.2M
- Sandeep GaonkarNaperville$1.8M
- Jon GrantChicago$1.4M
- David KempOak Lawn$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.